concept

CLDN1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CLDN1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

333Connections

0Hypotheses

1Analyses

50Outgoing

50Incoming

Summary

CLDN1 is a concept in neurodegeneration research. Key relationships include: therapeutic target, expressed in, activates. Associated with ALS, Als, Atherosclerosis. Connected to 146 entities in the SciDEX knowledge graph.

View on Wiki →

💡 Concept Info

Name	CLDN1
Key Genes/Proteins	EPHA2, OCLN
Related Diseases	chemoresistance, cancer stemness, Epidermal Barrier Function, Glioma, blood-brain barrier integrity

🔮 Predicted Structure: CLDN1 — AlphaFold O95832 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    CLDN1["CLDN1"]
    CLDN1 -->|"activates"| Ms["Ms"]
    CLDN1 -->|"activates"| Inflammation["Inflammation"]
    CLDN1 -->|"inhibits"| Als["Als"]
    CLDN1 -->|"target for"| Fibrosis["Fibrosis"]
    CLDN1 -->|"target for"| Hepatitis["Hepatitis"]
    CLDN1 -->|"target for"| Carcinoma["Carcinoma"]
    CLDN1 -->|"target for"| Cancer["Cancer"]
    h_6c83282d["h-6c83282d"] -->|"targets"| CLDN1
    IL4["IL4"] -->|"inhibits"| CLDN1
    IL13["IL13"] -->|"inhibits"| CLDN1
    OCLN["OCLN"] -->|"activates"| CLDN1
    TNF["TNF"] -->|"activates"| CLDN1
    FGF20["FGF20"] -->|"target for"| CLDN1
    BRG1["BRG1"] -->|"target for"| CLDN1
    NRCAM["NRCAM"] -->|"target for"| CLDN1
    NOTCH2["NOTCH2"] -->|"target for"| CLDN1
    EP300["EP300"] -->|"target for"| CLDN1

Outgoing (231)

Target	Relation	Type	Str
EPHA2	interacts_with	protein	0.95
chemoresistance	promotes	phenotype	0.95
cancer stemness	promotes	phenotype	0.95
EPHA2	inhibits	protein	0.90
Epidermal Barrier Function	associated_with	phenotype	0.85
Glioma Progression	downregulates	process	0.85
OCLN	co_mentioned_with	gene	0.80
Glioma	downregulates	disease	0.80
blood-brain barrier integrity	mediates	phenotype	0.75
Hepatitis	therapeutic_target	disease	0.75
Carcinoma	therapeutic_target	disease	0.75
Cancer	therapeutic_target	disease	0.75
Hepatocellular Carcinoma	therapeutic_target	disease	0.75
Glioblastoma Multiforme	suppresses	disease	0.70
Glioblastoma Multiforme	biomarker_for	disease	0.70
neural stem cells	inhibits	cell_type	0.70
neural stem cells	regulates	cell_type	0.70
Ms	activates	disease	0.65
Inflammation	activates	disease	0.65
Als	inhibits	disease	0.65
Fibrosis	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Ms	therapeutic_target	disease	0.65
Hepatitis	regulates	disease	0.65
Cirrhosis	therapeutic_target	disease	0.65
ALS	inhibits	disease	0.65
Prostate Cancer	therapeutic_target	disease	0.65
Infection	therapeutic_target	disease	0.65
Colorectal Cancer	therapeutic_target	disease	0.65
Liver Cancer	therapeutic_target	disease	0.65
Pulmonary Fibrosis	therapeutic_target	disease	0.65
Lung Cancer	therapeutic_target	disease	0.65
Pancreatic Cancer	therapeutic_target	disease	0.65
Gastric Cancer	therapeutic_target	disease	0.65
Als	expressed_in	disease	0.65
Atherosclerosis	expressed_in	disease	0.65
Inflammation	expressed_in	disease	0.65
Tumor	therapeutic_target	disease	0.65
Fibrosis	activates	disease	0.65
ALS	expressed_in	disease	0.65
MLCK	activates	gene	0.60
NRF2	activates	gene	0.60
ARNT	inhibits	gene	0.60
AHR	inhibits	gene	0.60
OCLN	expressed_in	gene	0.60
STAT6	inhibits	gene	0.60
TNF	activates	gene	0.60
APC	therapeutic_target	gene	0.60
AXIN1	therapeutic_target	gene	0.60

Incoming (102)

Source	Relation	Type	Str
Betulinic Acid	upregulates	compound	0.95
h-6c83282d	targets_gene	hypothesis	0.90
Gallic Acid	upregulates	compound	0.88
Tralokinumab	upregulates	drug	0.88
h-6c83282d	targets	hypothesis	0.80
IL4	inhibits	protein	0.72
IL13	inhibits	protein	0.72
CANCER	therapeutic_target	gene	0.70
OCLN	activates	gene	0.60
TNF	activates	gene	0.60
FGF20	therapeutic_target	gene	0.60
BRG1	therapeutic_target	gene	0.60
NRCAM	therapeutic_target	gene	0.60
NOTCH2	therapeutic_target	gene	0.60
EP300	therapeutic_target	gene	0.60
CTNNB1	therapeutic_target	gene	0.60
NEUROD1	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
ABCB1	therapeutic_target	gene	0.60
FOXM1	therapeutic_target	gene	0.60
LEF1	therapeutic_target	gene	0.60
SMARCA4	therapeutic_target	gene	0.60
TERT	therapeutic_target	gene	0.60
FZD7	therapeutic_target	gene	0.60
JAG1	therapeutic_target	gene	0.60
MITF	therapeutic_target	gene	0.60
GAIN	therapeutic_target	gene	0.60
AXIN2	therapeutic_target	gene	0.60
CD44	therapeutic_target	gene	0.60
ALDH1A1	therapeutic_target	gene	0.60
FGF18	therapeutic_target	gene	0.60
ATF3	therapeutic_target	gene	0.60
IL10	therapeutic_target	gene	0.60
DKK1	therapeutic_target	gene	0.60
PPARD	therapeutic_target	gene	0.60
AHR	inhibits	gene	0.60
ARNT	inhibits	gene	0.60
OCLN	associated_with	gene	0.60
CD81	therapeutic_target	gene	0.60
MLCK	activates	gene	0.60
NRF2	activates	gene	0.60
STAT6	inhibits	gene	0.60
OCLN	expressed_in	gene	0.60
CREBBP	therapeutic_target	gene	0.60
IFNG	expressed_in	gene	0.60
S100A8	expressed_in	gene	0.60
PPAR	activates	gene	0.60
IL22	expressed_in	gene	0.60
S100A9	expressed_in	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

neurodegeneration | 2026-04-01 | 20 hypotheses Top: 0.617

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

CLDN1

Understanding Entity Pages

Summary

Wiki Pages (20)

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

MLCK Gene

Microbiome Metabolomics and SCFA Therapy for CBS/PSP

IL13 — Interleukin 13

Blarcamesine (ALX-001)

epha2

Section 123: Microbiome-Gut-Brain Axis Interventions for CBS/PSP

Alpha-Synuclein Immunotherapy

Parkinson Basal Ganglia Circuit

PARKIN Gene

Parkin Protein

rock-inhibitor-therapy-parkinsons

Akkermansia muciniphila in CNS Disorders

Alpha-Synuclein Reduction Therapies for Neurodegenerative Diseases

AbbVie BRAIN Platform — Blood-Brain Barrier Delivery Technology

Alpha-Synuclein Aggregation Inhibitors